PMV Pharmaceuticals (PMVP) announced a transition on its board of directors. Laurie Stelzer, who has served as a member of the board since 2020, has been appointed chair of the board, succeeding Rich Heyman, effective at the company’s 2026 annual meeting of stockholders on June 4. Heyman’s term as a member and chair of the board will expire at the meeting, and Heyman will not stand for reelection. Stelzer is a seasoned CFO and public company board director, most recently serving as CFO at Kailera Therapeutics (KLRA).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMVP:
- PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI
- PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology
- PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)
- PMV Pharmaceuticals sees cash runway to end of 2Q27
- Pmv Pharmaceuticals, Inc. (PMVP) Q4 Earnings Cheat Sheet